Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of COVID-19 DNA Vaccines VB10.2129 and VB10.2210 in Healthy Adults
NCT05069623Phase 2Completed
- Sponsor
- Nykode Therapeutics
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of VB10.2129, VB10.2210 in coronavirus disease 2019 (COVID-19), sponsored by Nykode Therapeutics. Started Nov 2021; status: completed.
02
Drugs
VB10.2129VB10.2210
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05069623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069623.